US20130123194A1 - Autoclavable suspensions of cyclosporin a form 2 - Google Patents

Autoclavable suspensions of cyclosporin a form 2 Download PDF

Info

Publication number
US20130123194A1
US20130123194A1 US13/676,362 US201213676362A US2013123194A1 US 20130123194 A1 US20130123194 A1 US 20130123194A1 US 201213676362 A US201213676362 A US 201213676362A US 2013123194 A1 US2013123194 A1 US 2013123194A1
Authority
US
United States
Prior art keywords
cyclosporin
csa
formulation
change
pvp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/676,362
Inventor
Wendy M. Blanda
Hongwen M. Rivers
David A. Marsh
Michelle Luu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to US13/676,362 priority Critical patent/US20130123194A1/en
Publication of US20130123194A1 publication Critical patent/US20130123194A1/en
Assigned to ALLERGAN, INC. reassignment ALLERGAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LUU, MICHELLE, MARSH, DAVID A., BLANDA, WENDY M., RIVERS, HONGWEN M.
Priority to US15/171,866 priority patent/US9919028B2/en
Priority to US15/925,272 priority patent/US20180207230A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Definitions

  • the present invention solves these problems. Disclosed herein are formulations of cyclosporin A, combined with a parenterally-biocompatible suspending agent, which are sterile, exceptionally stable to heat sterilization, and have excellent long-term stability.
  • FIG. 3 shows x-ray powder diffraction pattern data of cyclosporin A Form 2 after autoclaving.
  • FIG. 4 shows congestion seen on slit lamp examination with eight different formulations.
  • FIG. 5 depicts characteristic X-ray powder diffraction (XRPD) patterns of CsA in a new crystalline form (designated as Form 2 herein), tetragonal form (designated as Form 1 herein), and orthorhombic form (designated as Form 3 herein).
  • XRPD characteristic X-ray powder diffraction
  • FIG. 6 depicts the XRPD diffractogram of CsA crystalline Form 2.
  • FIG. 7 depicts the water sorption/desorption profile of CsA Form 2.
  • FIG. 8 depicts MDSC analysis of CsA Form 2 recovered from 0.04% formulation with 1% PS80.
  • FIG. 9 shows gross ocular congestion after an injection of 100 ul of CMC, HEC, HPMC, Pluronic and PVP in phosphate buffered saline was administered subconjunctivally to New Zealand white rabbits. The rabbits were observed for seven days.
  • FIG. 10 shows gross ocular discharge in the experiment described in FIG. 9 .
  • FIG. 11 shows gross ocular swelling in the experiment described in FIG. 9 .
  • FIG. 12 shows the simulated XRPD pattern of cyclosporine A forms.
  • Cyclosporin A is a cyclic peptide having the following chemical structure:
  • Restasis® (Allergan, Inc., Irvine, Calif.), an emulsion comprising 0.05% (w/v) cyclosporin. Restasis® is approved in the United States to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
  • Cyclosporin A is known to exist in an amorphous form, liquid crystal form, tetragonal crystalline form (form 1), and an orthorhombic form (form 3).
  • a new crystalline form, cyclosporin A Form 2 has recently been discovered.
  • the XRPD pattern of CsA Form 2 differs significantly from the tetragonal form and orthorhombic form ( FIG. 1 ).
  • These major peaks are defined as those being unique to Form 2 relative to the orthorhombic or tetragonal forms; as well as, peaks having an intensity greater than 5 times the background.
  • the new crystalline form (Form 2) of CsA is a nonstoichiometric hydrate of Cyclosporin A.
  • the crystalline Form 2 is represented by the formula:
  • X is the number of molecules of water and varies from 0 to 3. In one embodiment, X in the above formula is 2.
  • Form 2 appears to be a kinetically stable form of CsA in aqueous suspensions. Suspensions containing Form 2 show no conversion to other known polymorphic or pseudomorphic forms upon storage. It has been found that Form 1 and the amorphous form convert to Form 2 in the presence of water.
  • thermogravimetric analysis combined with KF titration and vapor sorption desorption analysis suggest that CsA Form 2 is a non-stoichiometric hydrate of CsA.
  • the vapor sorption analysis of Cyclosporine Form 2 indicates that water content in the new crystal form reversibly varies with relative humidity as shown in FIG. 7 .
  • the new CsA form undergoes a phase transition to a liquid crystal or amorphous form at 124.4° C. prior to melting as indicated by the modulated differential calorimetric (MDSC) analysis ( FIG. 8 ).
  • MDSC modulated differential calorimetric
  • Cyclosporin A Form 2 may be obtained by suspending amorphous 0.05% cyclosporin A (w/v) in 1% Polysorbate 80, heating the solution to 65° C., holding it at that temperature for 24 hours, and then recovering the precipitate by vacuum filtration. One can then use the cyclosporin A Form 2 thus obtained to generate additional amounts, using Cyclosporin A Form 2 as a seed crystal; in this method, one suspends about 30 g cyclosporin A in a solution of 900 ml water containing 1% (w/v) Polysorbate 80, heats the solution to 65° C., and then seeds it with 0.2 g of cyclosporin A Form 2 at a temperature of 52° C. The solution is then stirred for about 22 hours at a temperature of between about 61° C. and 65° C., and then recovers the precipitate that results.
  • compositions of the invention are ophthalmically acceptable suspensions of Cyclosporin A form 2.
  • ophthalmically acceptable the inventors mean that the suspensions are formulated in such a way as to be non-irritating when administered to the eye of a mammal, such as a human.
  • the suspensions of the invention comprise cyclosporin A form 2 and a vehicle comprising a suspending agent such as hyaluronic acid, a cellulose, polyvinylpyrrolidone (PVP), Pluronic® copolymers based on ethylene oxide and propylene oxide, and Carbopol® polymers.
  • a suspending agent such as hyaluronic acid, a cellulose, polyvinylpyrrolidone (PVP), Pluronic® copolymers based on ethylene oxide and propylene oxide, and Carbopol® polymers.
  • the suspension comprises cyclosporin A Form 2 at a concentration of about 0.001% to about 10% (w/v). In one embodiment, the suspension comprises cyclosporin A form 2 at a concentration of about 0.001% (w/v) to about 0.01%, about 0.001% (w/v) to about 0.04% (w/v), about 0.001% (w/v) to about 0.03% (w/v), about 0.001% (w/v) to about 0.02% (w/v), or about 0.001% (w/v) to about 0.01% (w/v).
  • the suspension comprises cyclosporin A form 2 at a concentration of about 0.01% (w/v) to about 0.05%, about 0.01% (w/v) to about 0.04% (w/v), about 0.01% (w/v) to about 0.03% (w/v), about 0.01% (w/v) to about 0.02% (w/v), or about 0.01% (w/v) to about 0.01% (w/v).
  • the suspension comprises cyclosporin A form 2 at a concentration of about 0.01% (w/v) to about 0.1%, about 0.1% (w/v) to about 0.5% (w/v), about 0.01% (w/v) to about 1% (w/v), or about 1% (w/v) to about 10%.
  • the suspensions may comprise about 0.001% (w/v), about 0.002% (w/v), about 0.003% (w/v), about 0.004% (w/v), about 0.005% (w/v), about 0.006% (w/v), about 0.007% (w/v), about 0.008% (w/v), about 0.009% (w/v), about 0.01% (w/v), about 0.015% (w/v), about 0.02% (w/v), about 0.025% (w/v), about 0.03% (w/v), about 0.035% (w/v), about 0.04% (w/v), about 0.045% (w/v), about 0.05% (w/v), about 0.055% (w/v), about 0.06% (w/v), about 0.065% (w/v), about 0.07% (w/v), about 0.075% (w/v), about 0.08% (w/v), about 0.085% (w/v), about 0.09% (w/v), about 0.095% (w/v), about 0.1% (
  • CMC carboxymethyl cellulose.
  • HPMC hydroxypropyl methyl cellulose.
  • HEC hydroxyethyl cellulose.
  • HA hyaluronic acid.
  • Suspensions of the invention contain cyclosporin A Form 2 and a suspending agent.
  • the suspension also contains one or more of water, buffer, and salt, in sufficient quantities to provide a biocompatible formulation.
  • biocompatible the inventors mean that the suspension is appropriate for administration to the eye (for example, by parenteral administration).
  • the formulations of the invention may be manufactured by using either a heat-sterilized slurry of Form 2 cyclosporin mixed aseptically with a sterile parenterally-biocompatible suspending agent and other excipient; or by combining Form 2 cyclosporin with a parenterally-biocompatible suspending agent and other excipients and heat sterilizing the entire formulation.
  • the final viscosity of the drug formulation is sufficiently high to keep the cyclosporin suspended throughout the product's shelf-life.
  • the viscosity is sufficiently low to permit the final formulation to flow through a narrow gauge syringe, such as a 22, 23, 24, 25, or 26 gauge needle or narrower.
  • the formulation is sufficiently high to keep the cyclosporin suspended throughout the product's shelf-life, and also sufficiently low to permit the final formulation to flow through a syringe with a 22, 23, 24, 25, or 26 gauge needle or narrower.
  • Methods 1 and 2, below use hyaluronic acid as the suspending agent but, other suitable suspending agents may be substituted.
  • sterile hyaluronic acid is very expensive and that method 2 provides a unique method of sterilization, which allows the use of non-sterile hyaluronic acid by heat-reducing the polymer to the correct molecular weight range, so that it reaches the target viscosity range.
  • Method 2 therefore, requires precision manufacturing, where each new lot of hyaluronic acid may shift to a different viscosity range, under identical manufacturing conditions. Consequently, in order to assure the correct viscosity range is reached in every commercial batch, the heat cycle will need to be adaptive—that is—adjusted according to a set of guidelines and experiments on the raw material lot prior to manufacture of the drug product.
  • Method 2 prepares all steps of the formulation in a single vessel. These two methods allow for the rapid production of the drug product and consequently, have substantial value in saving one day or more of valuable manufacturing time over Method 1.
  • cyclosporin A Form 2 may be autoclaved and still retain its potency and stability.
  • hydrogel solutions are generally recognized as safe for topical use, very few have been used for parenteral administration, and none have been demonstrated to be safely injected through a 25 gauge needle (or narrower) into subconjunctival tissue at high hydrogel concentrations.
  • a high concentration of suspending agent (up to 25%) is necessary in order to maintain the suspendability of the 5-40% cyclosporin parenteral formulations described herein.
  • parenteral formulations for use in subconjunctival tissue are (1) injectable through a narrow-gauge needle, such as 25 gauge or narrower, in order to minimize tissue damage by the needle, to allow for quick healing of the needle entry-point, and to limit the back-flow of the injected formulation; (2) sterile; (3) biocompatible; and (4) sufficiently viscous to maintain suspendability throughout the shelf-life of the formulation and to prevent tissue reflux out of the subconjunctival space.
  • viscosity is sufficiently high to retain long-term suspendability of the drug but sufficiently low to allow the entire formulation to readily pass through a narrow gauge needle.
  • the formulations have a very high viscosity (e.g., ⁇ 100,000 cps) yet may still able to be injected out of syringe through a narrow-gauge needle.
  • a very high viscosity e.g., ⁇ 100,000 cps
  • the following table gives examples of such formulations.
  • compositions of the invention may be used to treat any condition of the eye which is known to be amenable to topical treatment with cyclosporin A (such as with Restasis®) at the concentrations stated here.
  • compositions of the invention may be used to treat patients suffering from dry eye, to treat blepharitis and meibomian gland disease, to restore corneal sensitivity that has been impaired due to refractive surgery on the eye, to treat allergic conjunctivitis and atopic and vernal keratoconjunctivitis, and to treat ptyregia, conjunctival and corneal inflammation, keratoconjuntivitis, graft versus host disease, post-transplant glaucoma, corneal transplants, mycotic keratitis, Thygeson's superficial punctate keratitis, uveitis, and Theodore's superior limbic keratoconjunctivitis, among other conditions.
  • the International Dry Eye Workshop defines dry eye as “a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface, accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.” It includes those conditions, such as keratoconjunctivitis sicca, that are caused by tear deficiency or excessive evaporation of tears.
  • Blepharitis is a chronic disorder producing inflammation of the anterior and posterior lid margin, with involvement of skin and its related structures (hairs and sebaceous glands), the mucocutaneous junction, and the meibomian glands. It can also affect the conjunctiva, tear film, and the corneal surface in advanced stages and may be associated with dry eye. Blepharitis is commonly classified into anterior or posterior blepharitis, with anterior affecting the lash bearing region of the lids, and posterior primarily affecting the meibomian gland orifices.
  • Meibomian gland disease most often occurs as one of three forms: primary meibomitis, secondary meibomitis, and meibomian seborrhea.
  • Meibomian seborrhea is characterized by excessive meibomian secretion in the absence of inflammation (hypersecretory meibomian gland disease).
  • Primary meibomitis by contrast, is distinguished by stagnant and inspissated meibomian secretions (obstructive hypersecretory meibomian gland disease).
  • Secondary meibomitis represents a localized inflammatory response in which the meibomian glands are secondarily inflamed in a spotty fashion from an anterior lid margin blepharitis.
  • Impaired corneal sensitivity often occurs after refractive surgery, such as photorefractive keratectomy, laser assisted sub-epithelium keratomileusis (LASEK), EPI-LASEK, customized transepithelial non-contact ablation, or other procedures in which the corneal nerves are severed. Impaired corneal sensitivity may also occur after viral infection, such as by HSV-1, HSV-2, and VZV viruses. Patients with impaired corneal sensitivity often complain that their eyes feel dry, even though tear production and evaporation may be normal, suggesting that “dryness” in such patients is actually a form of corneal neuropathy that results when corneal nerves are severed by surgery or inflamed after viral infection.
  • Allergic conjunctivitis is an inflammation of the conjunctiva resulting from hypersensitivity to one or more allergens. It may be acute, intermittent, or chronic. It occurs seasonally, that is, at only certain time of the year, or it occurs perennially, that is, chronically throughout the year. Symptoms of seasonal and perennial allergic conjunctivitis include, in addition to inflammation of the conjunctiva, lacrimation, tearing, conjunctival vascular dilation, itching, papillary hyperlasia, chemosis, eyelid edema, and discharge from the eye. The discharge may form a crust over the eyes after a night's sleep.
  • Atopic keratoconjunctivitis is a chronic, severe form of allergic conjunctivitis that often leads to visual impairment. Symptoms include itching, burning, pain, redness, foreign body sensation, light sensitivity and blurry vision. There is often a discharge, especially on awakening from a night's sleep; the discharge may be stringy, ropy, and mucoid. The lower conjunctiva is often more prominently affected than the upper conjunctiva. The conjunctiva may range from pale, edematous, and featureless to having the characteristics of advanced disease, including papillary hypertrophy, subepithelial fibrosis, formix foreshortening, trichiasis, entropion, and madurosis.
  • vernal keratoconjunctivitis is a severe form of allergic conjunctivitis, but it tends to affect the upper conjunctiva more prominently than the lower. It occurs in two forms. In the palpebral form, square, hard, flattened, closely packed papillae are present; in the bulbar (limbal) form, the circumcorneal conjunctiva becomes hypertrophied and grayish. Both forms are often accompanied by a mucoid discharge. Corneal epithelium loss may occur, accompanied by pain and photophobia, as may central corneal plaques and Trantas' dots.
  • the inventors explored formulations of four cyclosporin A polymorphic forms, the amorphous form, the tetragonal crystalline form (form 1), the orthorhombic form (form 3), and cyclosporin A Form 2.
  • the inventors explored the autoclavability of a series of concentrated solutions of various polymers (no drug) which, when loaded in a syringe, will flow through a narrow-gauge needle (25 gauge or narrower).
  • the polymers evaluated were as follows: cross-linked hyaluronic acid (Juvederm®), carbomer, carboxymethylcellulose-medium molecular weight, carboxymethylcellulose-high molecular weight, hydroxyethylcellulose, hydroxypropylcellulose, Pluronic F127 and polyvinylpyrrolidone K90. All of these are readily available from commercial suppliers.
  • Parenterally-biocompatible suspending agents were identified by injecting sterile concentrated solutions into the subconjunctival space and evaluating the toxicological response. An injection of 100 ul of the following polymers in phosphate buffered saline was administered subconjunctivally to New Zealand white rabbits and observed for a period of seven days.
  • the inventors prepared various formulations and evaluated their potency and purity, as well particle size distribution.

Abstract

Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This patent application claims priority to U.S. Provisional Patent Application No. 61/559,849, filed Nov. 15, 2011, the entire contents of which are hereby incorporated by reference
    • BACKGROUND
  • Aseptic processing of cyclosporin A suspensions in a hyaluronic acid media (a hydrogel used as a suspending agent), is complicated by the fact that both the drug and the hyaluronic acid need to be pre-sterilized. Pre-sterilized hyaluronic acid is extremely expensive, costing roughly $1 million dollars for a few kilograms (roughly $10,000 per ounce) of sterile raw material. Additionally, in the process of pre-sterilizing cyclosporin A, the drug is degraded upon irradiation, as shown below and in FIGS. 1 and 2:
  • TABLE 1
    Impact o Irradiation on Cyclosporin Stability
    Sterilization Form
    1 CsA Form 2 CsA Form 3 CsA Amorph, CsA
    Mode (Potency and Imp.) (Potency and Imp.) (Potency and Imp.) (Potency and Imp.)
    None 98.4% w/w 94.6% w/w 97.7% w/w 96.5% w/w
    Total Imp: 0.6% Total Imp: 0.6% Total Imp: 0.6% Total Imp: 0.7%
    15 kGy Gamma 93.9% w/w 91.8% w/w 94.3% w/w 92.1% w/w
    % Rel. Change: 4.5% % Rel. Change: 2.9% % Rel. Change: 3.6% % Rel. Change: 4.6%
    Total Imp: 1.7% Total Imp: 1.8% Total Imp: 1.3% Total Imp: 1.4%
    30 kGy Gamma 90.7% w/w 88.5% w/w 91.0% w/w 87.7% w/w
    % Rel. Change: 7.8% % Rel. Change: 6.4% % Rel. Change: 6.9% % Rel. Change: 9.2%
    Total Imp: 2.8% Total Imp: 2.4% Total Imp: 2.3% Total Imp: 2.3%
    E-Beam 92.6% w/w 90.3% w/w 93.4% w/w 92.0% w/w
    % Rel. Change: 5.9% % Rel. Change: 4.6% % Rel. Change: 4.5% % Rel. Change: 4.7%
    Total Imp: 1.5% Total Imp: 1.7% Total Imp: 1.6% Total Imp: 1.3%

    Cooling the cyclosporin during irradiation does not significantly improve the results, as shown in Table 2, below:
  • TABLE 2
    Impact on Cyclosporin Stabilily after irradiation under Cold Conditions
    Sterilization Form
    1 CsA Form 2 CsA Form 3 CsA Amorph, CsA
    Mode (Potency and Imp.) (Potency and Imp.) (Potency and Imp.) (Potency and Imp.)
    None 99.4% w/w 97.6% w/w 98.4% w/w 96.5% w/w
    Total Imp: 0.7% Total Imp: 0.5% Total Imp: 0.7% Total Imp: 0.7%
    Cold E-beam 94.6% w/w 91.1% w/w 94.6% w/w 92.3% w/w
    % Rel. Change: 4.8% % Rel. Change: 6.7% % Rel. Change: 3.9% % Rel. Change:
    Total Imp: 1.5% Total Imp: 1.5% Total Imp: 1.8% 4.4%
    Total Imp: 1.3%
    Regular E-Beam % Rel. Change: 5.9% % Rel. Change: 4.6% % Rel. Change: 4.5% % Rel. Change:
    (from Previous Total Imp: 1.5% Total Imp: 1.7% Total Imp: 1.6% 4.7%
    Study) % Relative Total Imp: 1.3%
    Change in
    Potency on
    Sterilization

    Additional levels of degradants need to be qualified in preclinical safety studies. Moreover, a suspension, prepared with only 90-95% of the labeled Cyclosporin A (due to the pre-sterilization process), has a substantial probability of failure to meet regulatory guidelines for shelf-life, since regulatory authorities generally prohibit shelf-lives below 90% of label.
  • The present invention solves these problems. Disclosed herein are formulations of cyclosporin A, combined with a parenterally-biocompatible suspending agent, which are sterile, exceptionally stable to heat sterilization, and have excellent long-term stability.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1 and 2 show change in cyclosporin A potency with change in crystal form and sterilization method.
  • FIG. 3 shows x-ray powder diffraction pattern data of cyclosporin A Form 2 after autoclaving.
  • FIG. 4 shows congestion seen on slit lamp examination with eight different formulations.
  • FIG. 5 depicts characteristic X-ray powder diffraction (XRPD) patterns of CsA in a new crystalline form (designated as Form 2 herein), tetragonal form (designated as Form 1 herein), and orthorhombic form (designated as Form 3 herein).
  • FIG. 6 depicts the XRPD diffractogram of CsA crystalline Form 2.
  • FIG. 7 depicts the water sorption/desorption profile of CsA Form 2.
  • FIG. 8 depicts MDSC analysis of CsA Form 2 recovered from 0.04% formulation with 1% PS80.
  • FIG. 9 shows gross ocular congestion after an injection of 100 ul of CMC, HEC, HPMC, Pluronic and PVP in phosphate buffered saline was administered subconjunctivally to New Zealand white rabbits. The rabbits were observed for seven days.
  • FIG. 10 shows gross ocular discharge in the experiment described in FIG. 9.
  • FIG. 11 shows gross ocular swelling in the experiment described in FIG. 9.
  • FIG. 12 shows the simulated XRPD pattern of cyclosporine A forms.
    •  DETAILED DESCRIPTION Cyclosporin A
  • Cyclosporin A (CsA) is a cyclic peptide having the following chemical structure:
  • Figure US20130123194A1-20130516-C00001
  • Its chemical name is cyclo[(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-N-methylglycyl-N-methyl-Lleucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl]. It is also known by the names cyclosporin, cyclosporine A, ciclosporin, and ciclosporin A. It is the active ingredient in Restasis® (Allergan, Inc., Irvine, Calif.), an emulsion comprising 0.05% (w/v) cyclosporin. Restasis® is approved in the United States to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
    • Cyclosporin A Form 2
  • Cyclosporin A is known to exist in an amorphous form, liquid crystal form, tetragonal crystalline form (form 1), and an orthorhombic form (form 3). A new crystalline form, cyclosporin A Form 2, has recently been discovered.
  • The XRPD pattern of CsA Form 2 differs significantly from the tetragonal form and orthorhombic form (FIG. 1). The major crystalline peaks for CsA form 2 appear at (2θ) when scanned by an X-ray diffractometer with X-ray source as Cu Kα radiation, λ=1.54 Å, at 30 kV/15 mA: 7.5, 8.8, 10.2, 11.3, 12.7, 13.8, 14.5, 15.6 and 17.5 (d-spacing in crystal lattice at about 11.8, 10.0, 8.7, 7.8, 7.0, 6.4, 6.1, 5.6 and 5.1 {acute over (Å)}, respectively, FIG. 2). These major peaks are defined as those being unique to Form 2 relative to the orthorhombic or tetragonal forms; as well as, peaks having an intensity greater than 5 times the background.
  • In one embodiment, the new crystalline form (Form 2) of CsA is a nonstoichiometric hydrate of Cyclosporin A. In another embodiment, the crystalline Form 2 is represented by the formula:
  • Figure US20130123194A1-20130516-C00002
  • wherein X is the number of molecules of water and varies from 0 to 3. In one embodiment, X in the above formula is 2.
  • Form 2 appears to be a kinetically stable form of CsA in aqueous suspensions. Suspensions containing Form 2 show no conversion to other known polymorphic or pseudomorphic forms upon storage. It has been found that Form 1 and the amorphous form convert to Form 2 in the presence of water.
  • The single crystal structure of the hydrate form of CsA Form 2 has been determined and the crystal structure parameters are listed in Table 2. These results indicate that Form 2 is unique compared to other known crystalline forms of cyclosporine A.
  • TABLE 1
    Crystal data and data collection parameters of crystal
    structure solution of CsA Form 2.
    formula C62H115N11O14
    formula weight 1238.67
    space group P 21 21 21 (No. 19)
    a (Å) 12.6390(5)
    b (Å) 19.7582(8)
    c (Å)  29.568(2)
    volume (Å3)  7383.8(7)
    Z 4
    dcalc(g cm−3) 1.114
    crystal dimensions (mm) 0.27 × 0.18 × 0.12
    temperature (K) 150
    radiation (wavelength in Å) Cu K2 (1.54184)
    monochromator confocal optics
    linear abs coef (mm−1) 0.640
    absorption correction applied empirical3
    transmission factors (min, max) 0.80, 0.93
    diffractometer Rigaku RAPID-II
    h, k, l range −13 to 13 −21 to 21 −32 to 21
    2θ range (deg) 5.38-115.00
    mosaicity (deg) 1.31
    programs used SHELXTL
    F000 2704.0
    weighting 1/[σ2(Fo2) + (0.0845P)2 + 0.0000P]
    where P = (Fo2 + 2Fo2)/3
    data collected 37360
    unique data 9964
    Rint 0.077
    data used in refinement 9964
    cutoff used in R-factor calculations Fo 2> 2.0s(Fo 2)
    data with I > 2.0s(I) 6597
    number of variables 834
    largest shift/esd in final cycle 0.00
    R(Fo) 0.061
    Rw(Fo 2) 0.145
    goodness of fit 1.037
    absolute structure determination Flack parameterb(0.0(3))

    The asymmetric unit of this CsA Form 2 contains one cyclosporine A molecule and two water molecules. It is possible that any small molecule that can hydrogen bond to water could play the role of space filler, which would give a range of potential structures running from the orthorhombic dihydrate to distorted monoclinic dihydrate The XRPD pattern calculated from the single-crystal structure is shown in FIG. 12 and it matches the experimental pattern shown in FIG. 2. These matching patterns further corroborate that Form 2 is a unique and pure crystalline form of cyclosporine A.
  • Without wishing to be bound by theory, thermogravimetric analysis combined with KF titration and vapor sorption desorption analysis (VSA) suggest that CsA Form 2 is a non-stoichiometric hydrate of CsA. The vapor sorption analysis of Cyclosporine Form 2 indicates that water content in the new crystal form reversibly varies with relative humidity as shown in FIG. 7. Similar to the tetragonal form, the new CsA form undergoes a phase transition to a liquid crystal or amorphous form at 124.4° C. prior to melting as indicated by the modulated differential calorimetric (MDSC) analysis (FIG. 8).
  • Cyclosporin A Form 2 may be obtained by suspending amorphous 0.05% cyclosporin A (w/v) in 1% Polysorbate 80, heating the solution to 65° C., holding it at that temperature for 24 hours, and then recovering the precipitate by vacuum filtration. One can then use the cyclosporin A Form 2 thus obtained to generate additional amounts, using Cyclosporin A Form 2 as a seed crystal; in this method, one suspends about 30 g cyclosporin A in a solution of 900 ml water containing 1% (w/v) Polysorbate 80, heats the solution to 65° C., and then seeds it with 0.2 g of cyclosporin A Form 2 at a temperature of 52° C. The solution is then stirred for about 22 hours at a temperature of between about 61° C. and 65° C., and then recovers the precipitate that results.
  • Further details regarding CsA Form 2 may be found in U.S. patent application Ser. No. 13/480,710, the entire contents of which are incorporated by reference herein.
    • Heat-Stable, Heat-Sterilized Suspensions of Cyclosporin a Form 2
  • Compositions of the invention are ophthalmically acceptable suspensions of Cyclosporin A form 2. By “ophthalmically acceptable,” the inventors mean that the suspensions are formulated in such a way as to be non-irritating when administered to the eye of a mammal, such as a human.
  • The suspensions of the invention comprise cyclosporin A form 2 and a vehicle comprising a suspending agent such as hyaluronic acid, a cellulose, polyvinylpyrrolidone (PVP), Pluronic® copolymers based on ethylene oxide and propylene oxide, and Carbopol® polymers.
  • In one embodiment, the suspension comprises cyclosporin A Form 2 at a concentration of about 0.001% to about 10% (w/v). In one embodiment, the suspension comprises cyclosporin A form 2 at a concentration of about 0.001% (w/v) to about 0.01%, about 0.001% (w/v) to about 0.04% (w/v), about 0.001% (w/v) to about 0.03% (w/v), about 0.001% (w/v) to about 0.02% (w/v), or about 0.001% (w/v) to about 0.01% (w/v). In another embodiment, the suspension comprises cyclosporin A form 2 at a concentration of about 0.01% (w/v) to about 0.05%, about 0.01% (w/v) to about 0.04% (w/v), about 0.01% (w/v) to about 0.03% (w/v), about 0.01% (w/v) to about 0.02% (w/v), or about 0.01% (w/v) to about 0.01% (w/v). In another embodiment, the suspension comprises cyclosporin A form 2 at a concentration of about 0.01% (w/v) to about 0.1%, about 0.1% (w/v) to about 0.5% (w/v), about 0.01% (w/v) to about 1% (w/v), or about 1% (w/v) to about 10%.
  • For example, the suspensions may comprise about 0.001% (w/v), about 0.002% (w/v), about 0.003% (w/v), about 0.004% (w/v), about 0.005% (w/v), about 0.006% (w/v), about 0.007% (w/v), about 0.008% (w/v), about 0.009% (w/v), about 0.01% (w/v), about 0.015% (w/v), about 0.02% (w/v), about 0.025% (w/v), about 0.03% (w/v), about 0.035% (w/v), about 0.04% (w/v), about 0.045% (w/v), about 0.05% (w/v), about 0.055% (w/v), about 0.06% (w/v), about 0.065% (w/v), about 0.07% (w/v), about 0.075% (w/v), about 0.08% (w/v), about 0.085% (w/v), about 0.09% (w/v), about 0.095% (w/v), about 0.1% (w/v), about 0.15% (w/v), about 0.2% (w/v), about 0.25% (w/v), about 0.3% (w/v), about 0.35% (w/v), about 0.4% (w/v), about 0.45% (w/v), about 0.5% (w/v), about 0.55% (w/v), about 0.6% (w/v), about 0.65% (w/v), about 0.7% (w/v), about 0.75% (w/v), about 0.8% (w/v), about 0.85% (w/v), about 0.9% (w/v), about 0.95% (w/v), or about 1.0% (w/v) cyclosporin A form 2.
  • Examples are provided in Table 3, below:
  • TABLE 3
    Autoclavable suspensions of cyclosporin A Form 2.
    Autoclave
    CsA Gelling Conditions
    (Crystal CsA Gelling Agent Agent (Temp
    Formulation form) (%) (Type) (%) (° C.)/min)
    1 2 20 CMC 5 121/10
    2 3 20 CMC 3 121/10
    3 NA 0 Carbopol Ultrez 1.5 121/15
    10
    4 NA 0 Carbopol Ultrez 2.0 121/15
    10
    5 NA 0 Carbopol Ultrez 2.5 121/15
    10
    6 NA 0 Carbopol Ultrez 1.0 121/15
    10
    7 NA 0 Carbopol Ultrez 4.0 121/15
    10
    8 2 5 CMC 3 121/15
    9 2 5 CMC 2 121/15
    10 2 20 CMC 10 121/15
    11 2 0 CMC 10 121/15
    12 2 5 HPMC 3 121/15
    13 2 5 HPMC 6 121/15
    14 2 20 HPMC 6 121/15
    15 2 20 HPMC 10 121/15
    16 2 5 HPMC 6 121/15
    17 2 20 HPMC 3 121/15
    18 2 5 HPMC 3 121/15
    19 2 20 HPMC 3 121/15
    20 2 10 HPMC 4.5 121/15
    21 2 10 HPMC 4.5 121/15
    22 2 10 HEC 3 121/15
    23 2 10 HEC 3 121/15
    24 2 30 HEC 1 121/15
    25 2 10 HA 3.5  121/15*
    26 2 10 HA 2.5 121/15
    27 2 30 HEC 1 121/15
    28 2 30 HA 1  121/15*
    29 2 10 HA 2.5 121/15
    30 2 10 HA 3.5 121/15
    31 2 10 HA 4.5 121/15
    32 2 30 HA 3.0 121/15
    33 2 20 HA 1.5 121/15
    34 2 20 HA 2.5 121/15
    35 2 20 HA 3.5 121/15
    36 2 10 HA 4 121/15,
    121/30, and
    123/15
    37 2 10 HA 4 121/15,
    121/30, and
    123/15
    38 2 10 HA 4 121/15,
    121/30, and
    123/15
    39 2 35 HA 1  121/15*
    40 2 5 HA 3.5  121/15*
    41 2 10 HA 3.5  121/15*
    42 2 20 HA 2.0  121/15*
    43 2 20 HA 2.0  121/15*
    44 2 10 HA 3.5  121/15*
    45 2 10 HA 3.5  121/15*
    46 2 25 N/A 0 120/15
    47 2 25 N/A 0 118/20
    48 2 25 N/A 0 120/12
    HEC1 2 5 HEC 5 121/15
    HEC2 2 20 HEC 5 121/15
    HEC3 2 5 HEC 2 121/15
    HEC4 2 20 HEC 2 121/15
    HEC5 2 5 HEC 5 121/15
    HEC6 2 20 HEC 5 121/15
    HEC7 2 5 HEC 2 121/15
    HEC8 2 20 HEC 2 121/15
    HEC9 2 10 HEC 3 121/15
    PVP1 2 10 PVP 25 121/15
    PVP2 2 10 PVP 25 121/15
    PVP3 2 10 PVP 15 121/15
    PVP4 2 10 PVP 15 121/15
    PVP5 2 25 PVP 25 121/15
    PVP6 2 25 PVP 25 121/15
    PVP7 2 25 PVP 15 121/15
    PVP8 2 25 PVP 15 121/15
    PVP9 2 10 PVP 25 121/15
    PVP10 2 25 PVP 25 121/15
    CsA = cyclosporin A.
    CMC = carboxymethyl cellulose.
    HPMC = hydroxypropyl methyl cellulose.
    HEC = hydroxyethyl cellulose.
    HA = hyaluronic acid.
    PVP = polyvinylpyrrolidone.
    *= slurry autoclaved prior to addition of gelling agent.
    • Methods of Preparation
  • Suspensions of the invention contain cyclosporin A Form 2 and a suspending agent. In another embodiment, the suspension also contains one or more of water, buffer, and salt, in sufficient quantities to provide a biocompatible formulation. By “biocompatible,” the inventors mean that the suspension is appropriate for administration to the eye (for example, by parenteral administration).
  • The formulations of the invention may be manufactured by using either a heat-sterilized slurry of Form 2 cyclosporin mixed aseptically with a sterile parenterally-biocompatible suspending agent and other excipient; or by combining Form 2 cyclosporin with a parenterally-biocompatible suspending agent and other excipients and heat sterilizing the entire formulation.
  • These methods address various important problems with cyclosporin formulation: 1) solid cyclosporin cannot be pre-sterilized by irradiation without significant drug degradation and formation of degradation products; 2) sterile filtration is also not feasible because the formulation is a suspension; and 3) terminal sterilization by heat will decrease gel viscosity. Also, in one embodiment, the final viscosity of the drug formulation is sufficiently high to keep the cyclosporin suspended throughout the product's shelf-life. In another embodiment, the viscosity is sufficiently low to permit the final formulation to flow through a narrow gauge syringe, such as a 22, 23, 24, 25, or 26 gauge needle or narrower. In still another embodiment, the formulation is sufficiently high to keep the cyclosporin suspended throughout the product's shelf-life, and also sufficiently low to permit the final formulation to flow through a syringe with a 22, 23, 24, 25, or 26 gauge needle or narrower.
  • Methods 1 and 2, below, use hyaluronic acid as the suspending agent but, other suitable suspending agents may be substituted.
  • It should be noted that sterile hyaluronic acid is very expensive and that method 2 provides a unique method of sterilization, which allows the use of non-sterile hyaluronic acid by heat-reducing the polymer to the correct molecular weight range, so that it reaches the target viscosity range. Method 2, therefore, requires precision manufacturing, where each new lot of hyaluronic acid may shift to a different viscosity range, under identical manufacturing conditions. Consequently, in order to assure the correct viscosity range is reached in every commercial batch, the heat cycle will need to be adaptive—that is—adjusted according to a set of guidelines and experiments on the raw material lot prior to manufacture of the drug product.
  • Furthermore, it should be noted that Method 2 prepares all steps of the formulation in a single vessel. These two methods allow for the rapid production of the drug product and consequently, have substantial value in saving one day or more of valuable manufacturing time over Method 1.
  • These methods depend on the inventors' surprising discovery that cyclosporin A Form 2 may be autoclaved and still retain its potency and stability. Other forms of cyclosporin—amorphous, Form 1 and Form 3—cannot be autoclaved, without unacceptable loss of drug substance from the suspension.
    • Method 1—Aqueous Slurry Method
  • The appropriate amount of cyclosporin A Form 2 is suspended and mixed in phosphate buffered saline solution and the slurry is heat sterilized by autoclave. In an aseptic environment, the appropriate amount of pre-sterilized hyaluronic acid is added to the sterile cyclosporin slurry, is mixed, and then dissolved. The drug product is brought to volume with sterile water for injection. The final product has a viscosity in the correct range to create a long-term stable suspension, while allowing the final formulation to flow through a syringe fitted with a narrow-gauge needle, such as 25 gauge needle or narrower.
    • Method 2—Single Vessel Method
  • An excess of non-sterile hyaluronic acid is dissolved in phosphate buffered saline solution. Cyclosporin A Form 2 is suspended and mixed. The resulting suspension formulation is heat-sterilized by autoclave (using an “adaptive” heat cycle), at the appropriate temperature and for the appropriate amount of time, to both sterilize the formulation and bring the viscosity into the desired range.
  • For parenteral formulations, it may be desirable to achieve a viscosity that is sufficiently high to keep the cyclosporin suspended throughout the product's shelf-life, and also sufficiently low to permit the final formulation to flow through a syringe with a 22, 23, 24, 25, or 26 gauge needle or narrower. While hydrogel solutions are generally recognized as safe for topical use, very few have been used for parenteral administration, and none have been demonstrated to be safely injected through a 25 gauge needle (or narrower) into subconjunctival tissue at high hydrogel concentrations. A high concentration of suspending agent (up to 25%) is necessary in order to maintain the suspendability of the 5-40% cyclosporin parenteral formulations described herein. In one embodiment, parenteral formulations for use in subconjunctival tissue are (1) injectable through a narrow-gauge needle, such as 25 gauge or narrower, in order to minimize tissue damage by the needle, to allow for quick healing of the needle entry-point, and to limit the back-flow of the injected formulation; (2) sterile; (3) biocompatible; and (4) sufficiently viscous to maintain suspendability throughout the shelf-life of the formulation and to prevent tissue reflux out of the subconjunctival space. In such formulations viscosity is sufficiently high to retain long-term suspendability of the drug but sufficiently low to allow the entire formulation to readily pass through a narrow gauge needle.
  • In one embodiment of the invention, the formulations have a very high viscosity (e.g., ≧100,000 cps) yet may still able to be injected out of syringe through a narrow-gauge needle. The following table gives examples of such formulations.
  • Formulation
    5% CsA, 3.5% HA 10% CsA, 3.5% HA 20% CsA, 2.0% HA
    (10203X) (10204X) (10205X)
    Viscosity: TBD Viscosity: 1,300,000 cps Viscosity: 700,000 cps
    Needle size BD TSK Steriject BD TSK Steriject BD TSK
    and type Precision 27G × 0.5″ Precision 27G × 0.5″ Precision Steriject
    Glide UTW (Ultra Glide UTW (Ultra Glide 27G × 0.5″
    27G × 0.5″ Thin Wall) 27G × 0.5″ Thin Wall) 27G × 0.5″ UTW (Ultra
    Needle Needle Needle Needle Needle Thin Wall)
    Needle
    Injectabiltiy ✓ ✓ ✓ ✓ ✓ ✓
    • Methods of Treatment
  • Compositions of the invention may be used to treat any condition of the eye which is known to be amenable to topical treatment with cyclosporin A (such as with Restasis®) at the concentrations stated here. For example, compositions of the invention may be used to treat patients suffering from dry eye, to treat blepharitis and meibomian gland disease, to restore corneal sensitivity that has been impaired due to refractive surgery on the eye, to treat allergic conjunctivitis and atopic and vernal keratoconjunctivitis, and to treat ptyregia, conjunctival and corneal inflammation, keratoconjuntivitis, graft versus host disease, post-transplant glaucoma, corneal transplants, mycotic keratitis, Thygeson's superficial punctate keratitis, uveitis, and Theodore's superior limbic keratoconjunctivitis, among other conditions.
  • The International Dry Eye Workshop (DEWS) defines dry eye as “a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface, accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.” It includes those conditions, such as keratoconjunctivitis sicca, that are caused by tear deficiency or excessive evaporation of tears.
  • Blepharitis is a chronic disorder producing inflammation of the anterior and posterior lid margin, with involvement of skin and its related structures (hairs and sebaceous glands), the mucocutaneous junction, and the meibomian glands. It can also affect the conjunctiva, tear film, and the corneal surface in advanced stages and may be associated with dry eye. Blepharitis is commonly classified into anterior or posterior blepharitis, with anterior affecting the lash bearing region of the lids, and posterior primarily affecting the meibomian gland orifices.
  • Meibomian gland disease most often occurs as one of three forms: primary meibomitis, secondary meibomitis, and meibomian seborrhea. Meibomian seborrhea is characterized by excessive meibomian secretion in the absence of inflammation (hypersecretory meibomian gland disease). Primary meibomitis, by contrast, is distinguished by stagnant and inspissated meibomian secretions (obstructive hypersecretory meibomian gland disease). Secondary meibomitis represents a localized inflammatory response in which the meibomian glands are secondarily inflamed in a spotty fashion from an anterior lid margin blepharitis.
  • Impaired corneal sensitivity often occurs after refractive surgery, such as photorefractive keratectomy, laser assisted sub-epithelium keratomileusis (LASEK), EPI-LASEK, customized transepithelial non-contact ablation, or other procedures in which the corneal nerves are severed. Impaired corneal sensitivity may also occur after viral infection, such as by HSV-1, HSV-2, and VZV viruses. Patients with impaired corneal sensitivity often complain that their eyes feel dry, even though tear production and evaporation may be normal, suggesting that “dryness” in such patients is actually a form of corneal neuropathy that results when corneal nerves are severed by surgery or inflamed after viral infection.
  • Allergic conjunctivitis is an inflammation of the conjunctiva resulting from hypersensitivity to one or more allergens. It may be acute, intermittent, or chronic. It occurs seasonally, that is, at only certain time of the year, or it occurs perennially, that is, chronically throughout the year. Symptoms of seasonal and perennial allergic conjunctivitis include, in addition to inflammation of the conjunctiva, lacrimation, tearing, conjunctival vascular dilation, itching, papillary hyperlasia, chemosis, eyelid edema, and discharge from the eye. The discharge may form a crust over the eyes after a night's sleep.
  • Atopic keratoconjunctivitis is a chronic, severe form of allergic conjunctivitis that often leads to visual impairment. Symptoms include itching, burning, pain, redness, foreign body sensation, light sensitivity and blurry vision. There is often a discharge, especially on awakening from a night's sleep; the discharge may be stringy, ropy, and mucoid. The lower conjunctiva is often more prominently affected than the upper conjunctiva. The conjunctiva may range from pale, edematous, and featureless to having the characteristics of advanced disease, including papillary hypertrophy, subepithelial fibrosis, formix foreshortening, trichiasis, entropion, and madurosis. In some patients the disease progresses to punctate epithelial erosions, corneal neovascularization, and other features of keratopathy which may impair vision. There is typically goblet cell proliferation in the conjunctiva, epithelial pseudotubular formation, and an increased number of degranulating eosinophils and mast cells in the epithelium. CD25+T lymphocytes, macrophages, and dendritic cells (HLA-DR.sup.+, HLA-CD1+) are significantly elevated in the substantia propria.
  • Like atopic keratoconjunctivitis, vernal keratoconjunctivitis is a severe form of allergic conjunctivitis, but it tends to affect the upper conjunctiva more prominently than the lower. It occurs in two forms. In the palpebral form, square, hard, flattened, closely packed papillae are present; in the bulbar (limbal) form, the circumcorneal conjunctiva becomes hypertrophied and grayish. Both forms are often accompanied by a mucoid discharge. Corneal epithelium loss may occur, accompanied by pain and photophobia, as may central corneal plaques and Trantas' dots.
    • EXAMPLES
  • The invention is further illustrated by the following examples.
  • When the inventors autoclaved aqueous suspensions of cyclosporin A, the drug particles aggregated, making the product unacceptable. Additionally, the inventors found that hyaluronic acid also degrades upon autoclaving, causing a marked drop in viscosity. Lower viscosity, in turn, reduces the suspendability of the drug particles and causes them to settle. Formulations having drug particles in suspension that too rapidly settle, or irreversibly settle, may be useful for laboratory tests, but are not commercially viable.
  • The inventors explored formulations of four cyclosporin A polymorphic forms, the amorphous form, the tetragonal crystalline form (form 1), the orthorhombic form (form 3), and cyclosporin A Form 2.
  • A suspension of form 1 converts to the amorphous form and aggregates upon autoclaving; clumping of the cyclosporin is also observed. Consequently, neither form 1 nor the amorphous form is suitable for autoclave stabilization. Furthermore, an autoclaved suspension of F3 in water lost 11-28% of its potency during autoclaving (Table 4); this, too, is unacceptable. In contrast, a suspension of Form 2 in water was quite stable to autoclaving, resisting degradation when compared to a pre-sterilization control. X-ray analysis of filtered solid from the Form 2 formulation also confirms that Form 2 is polymorphically stable to autoclaving (FIG. 3). These latter two findings are extremely surprising, considering the lack of either chemical or polymorphic stability of the other three forms.
  • The inventors explored the autoclavability of a series of concentrated solutions of various polymers (no drug) which, when loaded in a syringe, will flow through a narrow-gauge needle (25 gauge or narrower). The polymers evaluated were as follows: cross-linked hyaluronic acid (Juvederm®), carbomer, carboxymethylcellulose-medium molecular weight, carboxymethylcellulose-high molecular weight, hydroxyethylcellulose, hydroxypropylcellulose, Pluronic F127 and polyvinylpyrrolidone K90. All of these are readily available from commercial suppliers.
  • One hundred microliters of each of the autoclaved solutions was injected into rabbit conjunctiva, in order to evaluate the propensity for causing inflammation. Those polymers producing an inflammatory reaction were eliminated from consideration (FIG. 4, carbomer, both CMC's, and HPMC were eliminated). Additionally, Juvederm® was eliminated because it formed a long-lasting bleb which, in humans, might cause irritation as the eyelid moves over the site of injection. Both HPMC and Pluronic separated from the solution during/after autoclaving and consequently were also eliminated. Of the commercially viable hydrogels, only HEC and PVP demonstrated that they produced no inflammation in rabbit conjunctiva after autoclaving. These two hydrogels were used to formulate cyclosporin A suspensions for further evaluation. The results of the studies are shown in Table 5.
  • Initially, the inventors explored the possibility of heat-sterilizing a slurry of cyclosporin A of Form 1 (which converts to the amorphous form). This approach resulted in agglomeration of the drug and consequently, the formulation was not viable. Further studies, adding PVP to suppress the agglomeration of Form 1/amorphous form, also failed.
  • Since heat-sterilization of an aqueous suspension of cyclosporin did not appear to be viable, the inventors planned to prepare suspensions by aseptic technique, using pre-sterilize solid cyclosporin. Various solid cyclosporins ( Forms 1, 2, and 3 and amorphous) were treated with gamma or e-beam irradiation. In all cases, significant loss of drug (3-9%) occurred (FIG. 2 and Table 1). Furthermore, the substantial loss of drug indicates that high levels of degradation products (around 3-9%) are generated in the irradiation-sterilized material. These impurities may have negative toxicological and/or regulatory implications; consequently, this approach to sterilization appears to be undesirable.
  • TABLE 1
    Effect of Irradiation Sterilization on Cyclosporin (CsA) Drug Substance (solid)
    Sterilization Form 1 CsA Form 2 CsA Form 3 CsA Amorph. CsA
    Mode (Potency and Imp.) (Potency and Imp.) (Potency and Imp.) (Potency and Imp.)
    None 98.4% w/w 94.6% w/w 97.7% w/w 96.5% w/w
    Total Imp: 0.6% Total Imp: 0.6% Total Imp: 0.8% Total Imp: 0.7%
    15 kGy Gamma 93.9% w/w 91.8% w/w 94.3% w/w 92.1% w/w
    % Rel. Change: % Rel. Change: 2.9% % Rel. Change: 3.6% % Rel. Change:
    4.5% Total Imp: 1.8% Total Imp: 1.3% 4.6%
    Total Imp: 1.7% Total Imp: 1.4%
    33 kGy Gamma 90.7% w/w 88.5% w/w 91.0% w/w 87.7% w/w
    % Rel. Change: % Rel. Change: 6.4% % Rel. Change: 6.9% % Rel. Change:
    7.8% Total Imp: 2.4% Total Imp: 2.3% 9.2%
    Total Imp: 2.8% Total Imp: 2.3%
    E-Beam 92.6% w/w 90.3% w/w 93.4% w/w 92.0% w/w
    % Rel. Change: % Rel. Change: 4.6% % Rel. Change: 4.5% % Rel. Change:
    5.9% Total Imp: 1.7% Total Imp: 1.6% 4.7%
    Total Imp: 1.5% Total Imp: 1.3%
  • Subsequently, the inventors attempted to irradiate solid cyclosporin (Forms 1, 2, and 3 and amorphous), under the best conditions above, at cold temperatures. No significant improvement was noted with any of the Forms of cyclosporin (Table 2).
  • TABLE 2
    Effect of E-Beam Sterilization of Cyclosporins under Cold Conditions
    CsA Drug
    Substance Sample CsA Potency for CsA Potency 15 kGy CsA Potency 30 kGy Gamma CsA Potency
    Treatment Control Sample Gamma Treatment Treatment E-Beam 15 kGyTreatment
    Dry Ice 99.2% w/w 96.7% w/w 93.8% w/w 93.8% w/w
    (% Rel. Change: 2.5%) (% Rel. Change: 5.4%) (% Rel. Change: 5.4%)
    Cold Pack 96.5% w/w 93.0% w/w 92.1% w/w 93.2% w/w
    (% Rel. Change: 3.6%) (% Rel. Change: 4.6%) (% Rel. Change: 3.4%)
  • After it became apparent that irradiation of solid cyclosporins produced too much degradation, the inventors attempted to irradiate an aqueous suspension of cyclosporin, using hyaluronic acid as a suspending agent. This approach resulted in 4-10% degradation of the drug within the formulation.
  • TABLE 3
    Effect of Sterilization by Irradiation on Aqueous Suspensions of Cyclosporin [CsA] using
    Hyaluronic Acid [HA] as a Suspending Agent, at Various Temperatures
    CsA Potency for CsA Potency Post- % Relative Change in
    Sterilization Treatment Control Sample Sterilization Potency
    Cold Pack Control CsA 103.2% w/w Not Applicable Not Applicable
    Hydrogel Sample
    CsA-HA Sample (Cold Pack) 103.2% w/w 98.9% w/w  4.2%
    Treated with 15 kGy Gamma
    CsA-HA Sample (Cold Pack) 103.2% w/w 92.3% w/w 10.6%
    Treated with 30 kGy Gamma
    CsA-HA Sample (Cold Pack) 103.2% w/w 92.8% w/w 10.1%
    Treated with E-Beam (15 kGy)
  • Finally, the inventor turned their focus on steam sterilization of slurries and full formulations of cyclosporins. Slurries of Form 1 (which converts to amorphous) agglomerate during heat-sterilization. Slurries of Form 3, while physically stable and more chemically stable than Form 1, degraded significantly during heat sterilization. But, to the inventors' surprise, slurries of Form 2 were both physically and chemically stable (Tables 4 and 5).
  • TABLE 4
    Heat-Sterilization of Slurries of Cyclosporin (ScA) Form 2 (F-2) in Water
    CsA-F2 Slurry % CsA-F3 Slurry %
    Initial 96.86 101.41
    120 C. 15 min 96.88 88.61
    108 C. 60 min 106.69 71.72
  • TABLE 5
    Physical Stabiltiy of Forms 2 and 3 Before and After Heat Sterilization
    Formulation Material Spec. D90 D50 D10 Conditions
    A CsA-F2 Slurry 198.6313 116.8544 8.2711 Slurry control for steam
    control sterilization study
    A, autoclaved CsA-F2 Autoclaved 186.4431 99.902 7.0518 Autoclaved at 120 C. for 15
    slurry minutes
    A, autoclaved CsA-F2 Autoclaved 195.603 112.532 9.209 Autoclaved at 108 C. for 60
    slurry minutes
    B CsA-F3 Slurry 110.8281 63.3348 7.1711 Slurry control for steam
    control sterilization study
    B, autoclaved CsA-F3 Autoclaved 116.8761 67.523 12.1564 Autoclaved at 120 C. for 15
    slurry minutes
    B, autoclaved CsA-F3 Autoclaved 115.556 65.3309 10.5518 Autoclaved at 108 C. for 60
    slurry minutes
    % potency
    compared to CsA
    Formulation Material Conditions Form 2 standard
    A CsA-F2 Control 96.9
    A CsA-F2 120° C., 15 min 96.9
    A CsA-F2 108° C., 60 min 106.7
    B CsA-F3 Control 101.4
    B CsA-F3 120° C., 15 min 88.6
    B CsA-F3 108° C., 60 min 71.7
    • Ocular Congestion
  • Parenterally-biocompatible suspending agents were identified by injecting sterile concentrated solutions into the subconjunctival space and evaluating the toxicological response. An injection of 100 ul of the following polymers in phosphate buffered saline was administered subconjunctivally to New Zealand white rabbits and observed for a period of seven days.
  • 2% Carbomer (Carbopol Ultrez 10NF, Lubrizol)
  • 8% Carboxymethyl Cellulose (low viscosity CMC, Lubrizol)
  • 6% Carboxymethyl Cellulose (high viscosity CMC, Lubrizol)
  • 6% HEC (Ashland)
  • 6% HPMC (Dow Chemical)
  • Juvederm Ultra (Allergan, Inc)
  • Pluronic F127 (BASF)
  • Polyvinyl pyrrolidone (PVP K90, BASF)
  •
    tech Alternative
    type name source Lot# info vendor CoA Grade vendor Grade
    1 PVP PVP K30 Sigma_Aldrich BCBB7859 Mw 40K Sigma_Aldrich yes BASF PHEUR/
    81420-500G (or (PSO: USP/
    PSO R14247) 5% in NF/JP
    water,
    pH 3.6)
    2 PVP PVP K90 Sigma_Aldrich BCBB3954 Mw 360K Sigma_Aldrich yes BASF PHEUR/
    81440-250G USP/
    NF/JP
    3 PVP PVP 10 Sigma-Aldrich 050M0039 Mw 10K Sigma_Aldrich yes BASF PHEUR/
    PVP10-500G USP/NF
    4 HPMC Hypromellose PSO PM# XB14012N11 Sigma Dow yes USP/
    (tested to JP) 1018 H3785: Chemical PHEUR
    (R19424) 4000 cP,
    2% in water
    5 CMC Carboxy PSO 96413 CMC from
    methyl R19716Q Ashland/
    cellulose pending Aqualon is
    sodium NF/USP,
    6 CMC Carboxy PSO 96077
    methyl R19717
    cellulose
    sodium
    7 Hydroxyethyl Natrosol Kevin F0854 Type 250- Ashland HEC from
    cellulose (Type Warner HHX pharm Ashland./
    (HEC) 250-HHX Aqualon is
    pharm) USP/EP,
    8 Acrylate/C10- Carbopol Kevin EC742EK343 acrylate Lubrizol USP/
    30 Alkyl ETD Warner crosspolymer NF
    acrylate 2020NF (Viscosity,
    47-77K cP
    0.5% wt at
    pH 7.5)
    9 Carbomer Carbopol Kevin CC83RZG726 type A Lubrizol USP/
    Interpolymer Ultrez 10 Warner (Viscosity, NF
    NF 45-65K cP
    polymer 0.5% wt at
    pH 7.5)
    10 Carbomer- Carbopol Kevin EC863CC625 type C Lubrizol USP/
    Homopolymer 980 NF Warner (Viscosity, PHEUR/
    polymer 40-60K cP JPE
    0.5% wt at
    pH 7.5)
    tech Alternative
    type name source Lot# info vendor CoA Grade vendor Grade
    1 PVP PVP K30 Sigma_Aldrich BCBB7859 Mw 40K Sigma_Aldrich yes BASF PHEUR/
    81420-500G (or (PSO: USP/
    PSO R14247) 5% in NF/JP
    water,
    pH 3.6)
    2 PVP PVP K90 Sigma_Aldrich BCBB3954 Mw 360K Sigma_Aldrich yes BASF PHEUR/
    81440-250G USP/
    NF/JP
    3 PVP PVP 10 Sigma-Aldrich 050M0039 Mw 10K Sigma_Aldrich yes BASF PHEUR/
    PVP10-500G USP/NF
    4 HPMC Hypromellose PSO PM# XB14012N11 Sigma Dow yes USP/
    (tested to JP) 1018 H3785: Chemical PHEUR
    (R19424) 4000 cP,
    2% in water
    5 CMC Carboxy PSO 96413 CMC from
    methyl R19716Q Ashland/
    cellulose pending Aqualon is
    sodium NF/USP,
    6 CMC Carboxy PSO 96077
    methyl R19717
    cellulose
    sodium
    7 Hydroxyethyl Natrosol Kevin F0854 Type 250- Ashland HEC from
    cellulose (Type Warner HHX pharm Ashland./
    (HEC) 250-HHX Aqualon is
    pharm) USP/EP,
    8 Acrylate/C10- Carbopol Kevin EC742EK343 acrylate Lubrizol USP/
    30 Alkyl ETD Warner crosspolymer NF
    acrylate 2020NF (Viscosity,
    47-77K cP
    0.5% wt at
    pH 7.5)
    9 Carbomer Carbopol Kevin CC83RZG726 type A Lubrizol USP/
    Interpolymer Ultrez 10 Warner (Viscosity, NF
    NF 45-65K cP
    polymer 0.5% wt at
    pH 7.5)
    10 Carbomer- Carbopol Kevin EC863CC625 type C Lubrizol USP/
    Homopolymer 980 NF Warner (Viscosity, PHEUR/
    polymer 40-60K cP JPE
    0.5% wt at
    pH 7.5)

    Gross ocular congestion was shown to resolve within 7 days for CMC, HEC, HPMC, Pluronic and PVP. Ocular discharge was shown to resolve within three days. Ocular discharge resolved within 3 days for all groups except one. Results of the experiment are provided in FIGS. 9-11.
    • Impurity and Potency Analysis
  • The inventors prepared various formulations and evaluated their potency and purity, as well particle size distribution.
  •
    Impurities Analysis
    Composition Post-
    CsA Pre-Autoclave Autoclave
    Particle Potency (%) CsA Total CsA Total Absolute
    Size HEC No Impurities Impurities Change
    Formulation (μm) CSA (%) (%) autoclave Autoclave (% a/a) (% a/a) (% a/a)
    HEC-1 10 5 5 117.20% 115.70% 0.71% 0.69% −0.02%
    HEC-2 10 20 5 103.60% 116.60% 0.61% 0.61% 0.00%
    HEC-3 10 5 2 116.40% 118.80% 0.78% 0.70% −0.08%
    HEC-4 10 20 2 124.50% 124.70% 0.73% 0.69% −0.04%
    HEC-5 25 5 5 126.70% 116.60% 0.58% 0.58% 0.00%
    HEC-6 25 20 5 140.00% 147.40% 0.56% 0.56% 0.00%
    HEC-7 25 5 2 137.50% 142.50% 0.63% 0.59% −0.04%
    HEC-8 25 20 2 129.50% 119.70% 0.56% 0.57% 0.01%
    HEC-9 10 10 3 118.60% 111.70% 0.61% 0.62% 0.01%
    Composition
    CsA
    Particle Potency (%)
    Size PVP90 No
    Formualtion (μm) CSA (%) (%) autoclave Autoclave
    PVP-1 10 5 25 102.51 101.01
    PVP-2 10 20 25 113.81 111.82
    PVP-3 10 5 15 122.42 114.04
    PVP-4 10 20 15 120.28 123.3
    PVP-5 25 5 25 118.56 118.46
    PVP-6 25 20 25 114.55 115.28
    PVP-7 25 5 15 116.37 115.66
    PVP-8 25 20 15 120.9 124.05
    PVP-9 10 10 25 132.51 136.36
    PVP-10 25 10 25 118.03 126.6
    CsA Autoclave Conditions
    Crystal Temp (° C.)/ Particle size distribution
    Lot # Form Excipient Time (min.) D90 D50 D10
    1 2 5% CMC None 52.38 10.80 5.31
    2 2 5% CMC 121/10 18.02 11.55 5.74
    3 3 3% CMC None 28.01 12.09 6.84
    4 3 3% CMC 121/10 20.31 11.27 6.56
    5 2 None None 198.63 116.85 8.27
    6 2 None 120/15 186.44 99.90 7.05
    7 2 None 108/60 195.60 112.53 9.21
    8 3 None None 110.83 63.33 7.17
    9 3 None 121/15 116.88 67.52 12.16
    10 3 None 108/60 115.56 65.33 10.55
    11 2 None None 13.15 9.12 6.17
    12 2 None 121/15 14.15 9.12 6.42
    13 2 None None 14.14 9.66 6.44
    14 2 None 121/15 14.30 9.37 5.95
  • TABLE 5
    Key F2 Formulation Properties of Evaluated Polymers
    In-vivo
    Autoclavability tolerability (1 wk CSA-F2
    Syringeability (121 C., 15 min.) sub-conj.) Settling Potency
    Carbopol Max. conc. 4% No visible
    Figure US20130123194A1-20130516-P00899
    		 na na
    w/22 G change
    Figure US20130123194A1-20130516-P00899
    Carboxymethyl Cellulose Max. conc. 9% No visible
    Figure US20130123194A1-20130516-P00899
    		 na na
    (CMC) medium viscosity w/22 G change
    Figure US20130123194A1-20130516-P00899
    Carboxymethyl Cellulose Max. conc. 6% No visible
    Figure US20130123194A1-20130516-P00899
    		 na na
    (CMC) high viscosity w/22 G change
    Figure US20130123194A1-20130516-P00899
    Hydroxyethyl Cellulose Max. conc. 6% No visible Well tolerated. No settling in No loss in
    (HEC) w/22 G change Slight congestion comparison potency
    compared to with BDP gel post-
    saline under same autoclave
    conditions
    Hydroxypropyl Methyl Max. conc. 7%
    Figure US20130123194A1-20130516-P00899
    		 Well tolerated na na
    Cellulose (HPMC) w/22 G
    Figure US20130123194A1-20130516-P00899
    		 Comparable to
    Figure US20130123194A1-20130516-P00899
    		 saline.
    Figure US20130123194A1-20130516-P00899
    Juvederm Ultra 30G, as formulated Pre-sterilized by
    Figure US20130123194A1-20130516-P00899
    		 na na
    by manufacturer manufacturer
    Figure US20130123194A1-20130516-P00899
    Figure US20130123194A1-20130516-P00899
    Pluronic F127 Max. conc. 40%
    Figure US20130123194A1-20130516-P00899
    		 Tolerated. Slight na na
    w/22 G
    Figure US20130123194A1-20130516-P00899
    		 congestion and
    Figure US20130123194A1-20130516-P00899
    		 discharge
    Figure US20130123194A1-20130516-P00899
    		 compared to
    saline.
    Polyvinylpyrrolidone K90 Max. conc. 27% No visible ok
    Figure US20130123194A1-20130516-P00899
    		 No loss in
    (PVPK90) w/22 G change
    Figure US20130123194A1-20130516-P00899
    		 potency
    Figure US20130123194A1-20130516-P00899
    		 post-
    Figure US20130123194A1-20130516-P00899
    		 autoclave
    Figure US20130123194A1-20130516-P00899
    Figure US20130123194A1-20130516-P00899
    Figure US20130123194A1-20130516-P00899
    indicates data missing or illegible when filed

Claims (6)

What is claimed is:
1. A formulation comprising cyclosporin A form 2 and a vehicle selected from carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hyaluronic acid, polyvinylpyrrolidone, Carbopol Ultrez 10NF, and Pluronic F127.
2. The formulation of claim 2, wherein the cyclosporin A form 2 is at a concentration of about 0.01% to about 10%.
3. A method of making a formulation of cyclosporin A, the method comprising the steps of
a) dissolving cyclosporin A form 2 in solution;
b) autoclaving the solution;
c) adding a vehicle selected from carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hyaluronic acid, polyvinylpyrrolidone, Carbopol Ultrez 10NF, and Pluronic F127.
4. A method of making a formulation of cyclosporin A, the method comprising the steps of
a) dissolving in solution a vehicle selected from carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hyaluronic acid, polyvinylpyrrolidone, Carbopol Ultrez 10NF, and Pluronic F127;
b) adding to the solution cyclosporin A Form 2;
c) autoclaving the resulting mixture.
5. A method of treating a condition selected from dry eye, blepharitis, meibomian gland disease, impaired corneal sensitivity, allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and ptyregia, the method comprising the step of administering to a patient having such a condition the formulation of claim 3.
6. A method of treating a condition selected from dry eye, blepharitis, meibomian gland disease, impaired corneal sensitivity, allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and ptyregia, the method comprising the step of administering to a patient having such a condition the formulation of claim 4.
US13/676,362 2011-11-15 2012-11-14 Autoclavable suspensions of cyclosporin a form 2 Abandoned US20130123194A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/676,362 US20130123194A1 (en) 2011-11-15 2012-11-14 Autoclavable suspensions of cyclosporin a form 2
US15/171,866 US9919028B2 (en) 2011-11-15 2016-06-02 Autoclavable suspensions of cyclosporin A Form 2
US15/925,272 US20180207230A1 (en) 2011-11-15 2018-03-19 Autoclavable suspensions of cyclosporin a form 2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559849P 2011-11-15 2011-11-15
US13/676,362 US20130123194A1 (en) 2011-11-15 2012-11-14 Autoclavable suspensions of cyclosporin a form 2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/171,866 Division US9919028B2 (en) 2011-11-15 2016-06-02 Autoclavable suspensions of cyclosporin A Form 2

Publications (1)

Publication Number Publication Date
US20130123194A1 true US20130123194A1 (en) 2013-05-16

Family

ID=47192237

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/676,362 Abandoned US20130123194A1 (en) 2011-11-15 2012-11-14 Autoclavable suspensions of cyclosporin a form 2
US15/171,866 Active US9919028B2 (en) 2011-11-15 2016-06-02 Autoclavable suspensions of cyclosporin A Form 2
US15/925,272 Abandoned US20180207230A1 (en) 2011-11-15 2018-03-19 Autoclavable suspensions of cyclosporin a form 2

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/171,866 Active US9919028B2 (en) 2011-11-15 2016-06-02 Autoclavable suspensions of cyclosporin A Form 2
US15/925,272 Abandoned US20180207230A1 (en) 2011-11-15 2018-03-19 Autoclavable suspensions of cyclosporin a form 2

Country Status (12)

Country Link
US (3) US20130123194A1 (en)
EP (2) EP2779993B1 (en)
JP (2) JP6368244B2 (en)
KR (1) KR102015151B1 (en)
CN (2) CN104039308B (en)
AU (3) AU2012339701B8 (en)
BR (1) BR112014011733A2 (en)
CA (1) CA2856074C (en)
ES (1) ES2675269T3 (en)
HK (1) HK1202078A1 (en)
RU (1) RU2630970C2 (en)
WO (1) WO2013074616A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011449A1 (en) * 2014-07-18 2016-01-21 Allergan, Inc. Suspension compositions of cyclosporin a for subconjunctival and periocular injection
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
US11452783B2 (en) * 2017-02-14 2022-09-27 Gi Supply Tissue stain and use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108066745A (en) * 2017-12-26 2018-05-25 兆科药业（广州）有限公司 A kind for the treatment of process of Ciclosporin eye gel

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041671A1 (en) * 2000-04-07 2001-11-15 Napoli Guido Di Ophthalmic formulations
US20130023482A1 (en) * 2011-05-27 2013-01-24 Gore Anuradha V Crystalline form of cyclosporine a, methods of preparation, and methods for use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203564B (en) * 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
KR980008239A (en) * 1996-07-26 1998-04-30 김충환 Cyclosporin-containing pharmaceutical composition
US5981607A (en) * 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
DE19819273A1 (en) * 1998-04-30 1999-11-11 Pharmatec International S Giul Pharmaceutical ciclosporin formulation with improved biopharmaceutical properties, increased physical quality and stability as well as processes for its manufacture
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
EP1387676A2 (en) * 2001-05-01 2004-02-11 Angiotech Pharmaceuticals, Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
CN1456350A (en) * 2002-05-10 2003-11-19 刘继东 Eye cyclosporin gel
GB2391472B (en) 2002-08-02 2004-12-08 Satishchandra Punambhai Patel Pharmaceutical compositions
US20050059583A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
WO2005072701A1 (en) * 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2006003519A2 (en) * 2004-07-02 2006-01-12 Novagali Pharma Sa Use of emulsions for intra: and periocular injection
EP1655021B1 (en) 2004-11-09 2008-10-29 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
WO2006073786A2 (en) * 2004-12-30 2006-07-13 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
CN100431601C (en) * 2005-04-25 2008-11-12 北京大学 Cyclosporine microball preparation for treating endophthalmitis
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
DE102006051512A1 (en) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmaceutical drug compositions with cyclosporin
PL1834635T3 (en) * 2006-03-13 2012-01-31 Advancell Advanced In Vitro Cell Tech S A Stable nanocapsule systems for the administration of active molecules
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
FR2909876A1 (en) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Use of 2-(2-amino-3-benzoyl-phenyl)-acetamide and its derivatives for the preparation of a composition for the treatment of skin diseases e.g. rosacea, psoriasis or atopic dermatitis
US20090286718A1 (en) * 2008-01-04 2009-11-19 Sirion Therapeutics, Inc. Stable Aqueous Cyclosporin Compositions
JP5661035B2 (en) * 2008-07-10 2015-01-28 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Cyclosporine derivatives for the treatment of eye and skin diseases and conditions
US20100303915A1 (en) * 2009-06-02 2010-12-02 Abbott Medical Optics Inc. Therapeutic opthalmic emulsions
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041671A1 (en) * 2000-04-07 2001-11-15 Napoli Guido Di Ophthalmic formulations
US20130023482A1 (en) * 2011-05-27 2013-01-24 Gore Anuradha V Crystalline form of cyclosporine a, methods of preparation, and methods for use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Definition of cyclosporine, from http://medical-dictionary.thefreedictionary.com/p/cyclosporine, pages 1-5, accessed 3/27/2014. *
Hyaluronic Acid, from http://www.hyalogic.com/main/about_hyaluronic_acid, pages 1-6, accessed 4/11/2014. *
Maleki et al, Anomalous Viscosity Behavior in Aqueous Solutions of Hyaluronic Acid, Polymer Bulletin, 2007, 59, pages 217-226. *
Parenteral Routes of Administration, from Study online at quizlet.com/_6z8rb, pages 1-2, accessed 10/1/2014. *
Syringe Needle Gauge Chart, from http://www.sigmaaldrich.com/chemistry/stockroom-reagents/learning-center/technical-libr..., pages 1-2, accessed 10/1/2014. *
Wilson et al, How to Give Intravitreal Injections, Eyenet, 2013, pages 45-47. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
WO2016011449A1 (en) * 2014-07-18 2016-01-21 Allergan, Inc. Suspension compositions of cyclosporin a for subconjunctival and periocular injection
RU2713953C2 (en) * 2014-07-18 2020-02-11 Аллерган, Инк. Suspension compositions of cyclosporine a for subconjunctival and periocular injection
US10780048B2 (en) 2014-07-18 2020-09-22 Allergan, Inc. Suspension compositions of cyclosporin A for subconjunctival and periocular injection
AU2015289387B2 (en) * 2014-07-18 2020-10-22 Allergan, Inc. Suspension compositions of cyclosporin A for subconjunctival and periocular injection
EP3169308B1 (en) 2014-07-18 2021-01-27 Allergan, Inc. Suspension compositions of cyclosporin a for subconjunctival and periocular injection
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
US11452783B2 (en) * 2017-02-14 2022-09-27 Gi Supply Tissue stain and use thereof

Also Published As

Publication number Publication date
AU2017276176A1 (en) 2018-01-18
CN104039308A (en) 2014-09-10
CA2856074C (en) 2017-07-04
JP2018165270A (en) 2018-10-25
EP3403645A1 (en) 2018-11-21
AU2012339701A1 (en) 2014-06-05
AU2019204332A1 (en) 2019-07-11
JP2015502351A (en) 2015-01-22
RU2630970C2 (en) 2017-09-15
AU2012339701B2 (en) 2017-10-05
BR112014011733A2 (en) 2017-05-09
US9919028B2 (en) 2018-03-20
US20160271207A1 (en) 2016-09-22
JP6368244B2 (en) 2018-08-01
AU2012339701B8 (en) 2017-11-16
AU2019204332B2 (en) 2020-12-24
AU2012339701A8 (en) 2017-11-16
KR102015151B1 (en) 2019-08-27
EP2779993B1 (en) 2018-04-04
CN108714137A (en) 2018-10-30
US20180207230A1 (en) 2018-07-26
HK1202078A1 (en) 2015-09-18
KR20140104960A (en) 2014-08-29
ES2675269T3 (en) 2018-07-10
RU2014123466A (en) 2015-12-27
CN108714137B (en) 2022-02-01
WO2013074616A1 (en) 2013-05-23
JP6829706B2 (en) 2021-02-10
CA2856074A1 (en) 2013-05-23
CN104039308B (en) 2018-06-05
EP2779993A1 (en) 2014-09-24

Similar Documents

Publication Publication Date Title
US20180207230A1 (en) Autoclavable suspensions of cyclosporin a form 2
US20210236590A1 (en) Sustained action formulation of cyclosporin form 2
JP2020040968A (en) Suspensions of cyclosporin a form 2

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLERGAN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLANDA, WENDY M.;RIVERS, HONGWEN M.;MARSH, DAVID A.;AND OTHERS;SIGNING DATES FROM 20111112 TO 20111122;REEL/FRAME:034747/0676

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION